Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0224)
Drug Name
Bosutinib
Synonyms
Bosutinib; Bosutinib (SKI-606); BOSULIF; SKI 606; SKI-606; SKI606; 380843-75-4; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 5018V4AEZ0; CHEBI:39112; CHEMBL288441; MFCD07367846; UNII-5018V4AEZ0
Indication Chronic myelogenous leukaemia [ICD11: 2A20] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 530.4 Topological Polar Surface Area 82.9
Heavy Atom Count 36 Rotatable Bond Count 9
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
5328940
PubChem SID
8034215 ; 11061176 ; 14720373 ; 14885411 ; 17397405 ; 26676000 ; 26746630 ; 39301565 ; 53641516 ; 56459346 ; 57361290 ; 85246176 ; 92721109 ; 103220856 ; 113911152 ; 118844931 ; 124950167 ; 125011711 ; 125349351 ; 126627733 ; 126647930 ; 126666992 ; 126731247 ; 134339019 ; 134964339 ; 135246638 ; 135642791 ; 135684978 ; 135685144 ; 135685145 ; 135685164 ; 135697655 ; 136340225 ; 136368026 ; 136920303 ; 137127131 ; 139943916 ; 143495997 ; 144115749 ; 152041940 ; 152234943 ; 152258097 ; 152344342 ; 160646936 ; 162011701 ; 162170730 ; 162201602 ; 162256836 ; 163884826 ; 164041898
ChEBI ID
ChEBI:39112
CAS Number
380843-75-4
TTD Drug ID
D0OB0F
Formula
C26H29Cl2N5O3
Canonical SMILES
CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
InChI
1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
InChIKey
UBPYILGKFZZVDX-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
N-desmethyl bosutinib DM006337
5328944
Oxidation - N-desmethylation 1 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006807 Bosutinib N-desmethyl bosutinib Oxidation - N-desmethylation CYP3A4 [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 Bosutinib was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
3 Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.